A Phase I/II Trial of Fairly Brief Androgen Suppression and Stereotactic Radiation Therapy for High-Risk Prostate Cancer (FASTR-2): Preliminary Results and Toxicity Analysis by Laura Callan, MD, MASc, Glenn Bauman, MD, Jeff Chen, PhD, Michael Lock, MD, Tracy Sexton, MD, PhD, David D'Souza, MD, George Rodrigues, MD, PhD

Get full text

Utilization of Salvage and Systemic Therapies for Recurrent Prostate Cancer as a Result of 18F-DCFPyL PET/CT Restaging by Wei Liu, MD, Katherine Zukotynski, MD, PhD, FRCPC, Louise Emmett, MD, FRACP, Hans T. Chung, MD, FRCPC, Peter Chung, MD, FRCPC, Robert Wolfson, MD, FRCPC, Irina Rachinsky, MD, MSc, FRCPC, Anil Kapoor, MD, FRCSC, Ur Metser, MD, FRCPC, Andrew Loblaw, MD, MSc, FRCPC, Gerard Morton, MB, FRCPC, Tracy Sexton, MD, PhD, FRCPC, Michael Lock, MD, FRCPC, Joelle Helou, MD, MSc, Alejandro Berlin, MD, MSc, Colm Boylan, MB, FRCPC, Susan Archer, BSc, Gregory R. Pond, PhD, PStat, Glenn Bauman, MD, FRCPC

Get full text